INDUCING APOPTOSIS IN QUIESCENT CELLS

• US 20130064815A1
• Filed: 09/12/2012
• Published: 03/14/2013
• Est. Priority Date: 09/12/2011
• Status: Abandoned Application

• Current Assignee: The Trustees of Princeton University (Princeton University)
• Original Assignee: The Trustees of Princeton University (Princeton University)
• Inventors: Coller, Hilary
• Application Number:
  US13/612,199
• Publication Number:
  US 20130064815A1
• Time in Patent Office: Days
• US Class Current: 424/133.1
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/5685 having an oxo group in position 17, e.g. androsterone
• CPC Class Codes: A61K 31/7048 having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin , digitoxin or digoxin
• CPC Class Codes: A61K 45/06 Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: C07K 16/00 Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies antibodies with enzymatic activity, e.g. abzymes C12N9/0002
• CPC Class Codes: G01N 2510/00 Detection of programmed cell death, i.e. apoptosis

Abstract

Compositions comprising an autophagy inhibitor and at least one of an NADPH modulator or a glutathione inhibitor are provided. Methods of inhibiting or killing a quiescent cell are provided. Methods of treating cancer are provided. Methods of identifying compositions that inhibit or kill quiescent cells are provided. Methods of identifying compositions that inhibit or kill quiescent cells are provided. Methods of inducing apoptosis are provided. Methods of sensitizing quiescent cells to proteasome inhibitors are provided.

Claims

1. A composition comprising an autophagy inhibitor and at least one of an NADPH modulator or a glutathione modulator.

2. The composition of claim 1, wherein the autophagy inhibitor includes a substance selected from the group consisting of a macrolide antibiotic, bafilomycin, concanamycin, an inhibitor of vacuolar type H+-ATPase, an inhibitor of lysosomal acidification, an antimalarial substance, chloroquine, hydroxychloroquine, micronized hydroxychloroquine, quinacrine, an analog of a macrolide antibiotic, an analog of bafilomycin, chloroquine analogs having a lateral alkyl side chain and dialkyl substitution on the lateral side chain, 7-chloro-N-(3-(4-(7-trifluoromethyl)quinolin-4-yl)piperazin-1-yl)propyl)quinolin-4-amine, {3-[4-(7-chloro-quinolin-4-yl)-piperazin-1-yl]-propyl}-(7-rifluoromethyl-quinolin-4-yl)-amine, 3-methyladenine, an siRNA targeting a protein in the autophagy pathway, an shRNA targeting a protein within the autophagy pathway, an siRNA targeting atg5, an siRNA targeting atg7, an siRNA targeting lc3/atg8, an siRNA targeting beclin1, an shRNA targeting atg5, an shRNA targeting atg7, an shRNA targeting lc3/atg8, and an shRNA targeting beclin 1, or a vector or virus encoding any of the aforementioned peptides, proteins, or RNAs, or an analog or precursor of any of the aforementioned compounds, or a pharmaceutically acceptable salt of any of the foregoing substances.

3. The composition of claim 1, wherein the at least one of an NADPH modulator or a glutathione modulator includes a substance selected from the group consisting of an inhibitor of glucose-6-phosphate dehydrogenase, an inhibitor of 6 phosphogluconate dehydrogenase, an inhibitor of isocitrate dehydrogenase 1, an inhibitor of isocitrate dehydrogranse 2, an inhibitor of an enzyme in the pentose phosphate pathway, dehydroepiandrosterone, 16α

-fluoro-5-androsten-17-one, 16α

-fluoro-5α

-androstan-17-one, 3-β

-methylandrost-5-en-17-one, somatostatin, a peptide of hypothalamic origin, an inhibitor of transketolase, an analog of a tranketolase inhibitor, a thiamine analog, oxythiamine, a non-charged thiamine analog, a micronized DHEA, DHEA, an siRNA targeting a pentose phosphate pathway enzyme, an siRNA targeting gluocse-6-phosphate dehydrogenase, an siRNA targeting nrf2, an siRNA targeting srbp, an shRNA targeting a pentose phosphate pathway enzyme, an shRNA targeting gluocse-6-phosphate dehydrogenase, an shRNA targeting nrf2, an shRNA targeting srbp, and butathione sulfoximine, or a vector or virus encoding any of the aforementioned peptides, proteins, or RNAs, or an analog or precursor of any of the aforementioned compounds, or a pharmaceutically acceptable salt of any of the foregoing substances.

4. The composition of claim 1 further comprising an anti-cancer chemotherapeutic agent or a pharmaceutically acceptable salt thereof other than the autophagy inhibitor and other than the at least one of an NADPH modulator or a glutathione modulator.

5. The composition of any of claim 1 further comprising at least one substance selected from the group consisting of oxaliplatin, capecitabine, bevacizumab, docetaxel, paclitaxel, carboplatin, ixabepilone, androstenedione, testosterone, a precursor of any of the aforementioned compounds and a pharmaceutically acceptable salt of any of the foregoing substances.

6. The composition of claim 1, wherein the at least one of an NADPH modulator or a glutathione modulator is micronized DHEA or a pharmaceutically acceptable salt thereof, and the autophagy inhibitor is micronized hydroxychloroquine or a pharmaceutically acceptable salt thereof.

7. The composition of claim 1, wherein the at least one of an NADPH modulator or a glutathione modulator is DHEA.

8. The composition of claim 1, wherein the autophagy inhibitor is bafilomycin.

9. The composition of claim 1 further comprising a targeting agent adapted to deliver the at least one of an NADPH modulator or a glutathione modulator or the autophagy inhibitor to a tumor cell.

10. The composition of claim 1 further comprising a pharmaceutically acceptable carrier.

11. The composition of claim 10, wherein the pharmaceutically acceptable carrier includes at least one substance selected from the group consisting of ion exchangers, alumina, aluminum stearate, lecithin, serum proteins, human serum albumin, buffer substances, phosphates, glycine, sorbic acid, potassium sorbate, partial glyceride mixtures of saturated vegetable fatty acids, water, salts, electrolytes, protamine sulfate, disodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride, zinc salts, colloidal silica, magnesium trisilicate, polyvinyl pyrrolidone, cellulose-based substances, polyethylene glycol, sodium carboxymethylcellulose, waxes, polyethylene glycol, starch, lactose, dicalcium phosphate, microcrystalline cellulose, sucrose, talc, magnesium carbonate, kaolin, non-ionic surfactants, edible oils, physiological saline, bacteriostatic water, Cremophor EL™

(BASF, Parsippany, N.J.), and phosphate buffered saline (PBS).

12. The composition of claim 1 further comprising a reactive oxygen species modulator or a pharmaceutically acceptable salt thereof.

13. The composition of claim 1 further comprising a proteasome inhibitor or a pharmaceutically acceptable salt thereof.

14. The composition of claim 13, wherein the proteasome inhibitor is selected from the group consisting of MG132 and bortezomib.

15. The composition of claim 13, wherein the proteasome inhibitor is bortezomib.

16. A method of inhibiting or killing a quiescent cell comprising exposing the quiescent cell to at an autophagy inhibitor and at least one of an NADPH modulator or a glutathione modulator.

17. The method of claim 16, wherein the inhibitor of autophagy includes a substance selected from the group consisting of a macrolide antibiotic, bafilomycin, concanamycin, an inhibitor of vacuolar type H+-ATPase, an inhibitor of lysosomal acidification, an antimalarial substance, chloroquine, hydroxychloroquine, micronized hydroxychloroquine, quinacrine, an analog of a macrolide antibiotic, an analog of bafilomycin, chloroquine analogs having a lateral alkyl side chain and dialkyl substitution on the lateral side chain, 7-chloro-N-(3-(4-(7-trifluoromethyl)quinolin-4-yl)piperazin-1-yl)propyl)quinolin-4-amine, {3-[4-(7-chloro-quinolin-4-yl)-piperazin-1-yl]-propyl}-(7-rifluoromethyl-quinolin-4-yl)-amine, an siRNA targeting a protein in the autophagy pathway, an shRNA targeting a protein within the autophagy pathway, an siRNA targeting atg5, an siRNA targeting atg7, an siRNA targeting lc3/atg8, an siRNA targeting beclin1, an shRNA targeting atg5, an shRNA targeting atg7, an shRNA targeting lc3/atg8, and an shRNA targeting beclin 1, or a vector or virus encoding any of the aforementioned peptides, proteins, or RNAs, or an analog or precursor of any of the aforementioned compounds, or a pharmaceutically acceptable salt of any of the foregoing substances.

18. The method of claim 16, wherein the at least one of an NADPH modulator or a glutathione modulator includes a substance selected from the group consisting of an inhibitor of glucose-6-phosphate dehydrogenase, an inhibitor of 6 phosphogluconate dehydrogenase, an inhibitor of isocitrate dehydrogenase 1, an inhibitor of isocitrate dehydrogranse 2, an inhibitor of an enzyme in the pentose phosphate pathway, dehydroepiandrosterone, 16α

-fluoro-5-androsten-17-one, 16α

-fluoro-5α

-androstan-17-one, 3-β

-methylandrost-5-en-17-one, somatostatin, a peptide of hypothalamic origin, an inhibitor of transketolase, an analog of a tranketolase inhibitor, a thiamine analog, oxythiamine, a non-charged thiamine analog, a micronized DHEA, DHEA, an siRNA targeting a pentose phosphate pathway enzyme, an siRNA targeting gluocse-6-phosphate dehydrogenase, an siRNA targeting nrf2, an siRNA targeting srbp, an shRNA targeting a pentose phosphate pathway enzyme, an shRNA targeting gluocse-6-phosphate dehydrogenase, an shRNA targeting nrf2, an shRNA targeting srbp, and butathione sulfoximine, or a vector or virus encoding any of the aforementioned peptides, proteins, or RNAs, or an analog or precursor of any of the aforementioned compounds, or a pharmaceutically acceptable salt of any of the foregoing substances.

19. The method of claim 16 further comprising administering a reactive oxygen species modulator.

20. The method of claim 16 further comprising administering a proteasome inhibitor.

21. A method of treating cancer comprising administering an autophagy inhibitor and at least one of an NADPH modulator or a glutathione modulator to a cancer patient.

22. The method of claim 21, wherein the inhibitor of autophagy includes a substance selected from the group consisting of a macrolide antibiotic, bafilomycin, concanamycin, an inhibitor of vacuolar type H+-ATPase, an inhibitor of lysosomal acidification, an antimalarial substance, chloroquine, hydroxychloroquine, micronized hydroxychloroquine, quinacrine, an analog of a macrolide antibiotic, an analog of bafilomycin, chloroquine analogs having a lateral alkyl side chain and dialkyl substitution on the lateral side chain, 7-chloro-N-(3-(4-(7-trifluoromethyl)quinolin-4-yl)piperazin-1-yl)propyl)quinolin-4-amine, {3-[4-(7-chloro-quinolin-4-yl)-piperazin-1-yl]-propyl}-(7-rifluoromethyl-quinolin-4-yl)-amine, an siRNA targeting a protein in the autophagy pathway, an shRNA targeting a protein within the autophagy pathway, an siRNA targeting atg5, an siRNA targeting atg7, an siRNA targeting lc3/atg8, an siRNA targeting beclin1, an shRNA targeting atg5, an shRNA targeting atg7, an shRNA targeting lc3/atg8, and an shRNA targeting beclin 1, or a vector or virus encoding any of the aforementioned peptides, proteins, or RNAs, or an analog or precursor of any of the aforementioned compounds, or a pharmaceutically acceptable salt of any of the foregoing substances.

23. The method of claim 21, wherein the at least one of an NADPH modulator or a glutathione modulator includes a substance selected from the group consisting of an inhibitor of glucose-6-phosphate dehydrogenase, an inhibitor of 6 phosphogluconate dehydrogenase, an inhibitor of isocitrate dehydrogenase 1, an inhibitor of isocitrate dehydrogranse 2, an inhibitor of an enzyme in the pentose phosphate pathway, dehydroepiandrosterone, 16α

-fluoro-5-androsten-17-one, 16α

-fluoro-5α

-androstan-17-one, 3-β

-methylandrost-5-en-17-one, somatostatin, a peptide of hypothalamic origin, an inhibitor of transketolase, an analog of a tranketolase inhibitor, a thiamine analog, oxythiamine, a non-charged thiamine analog, a micronized DHEA, DHEA, an siRNA targeting a pentose phosphate pathway enzyme, an siRNA targeting gluocse-6-phosphate dehydrogenase, an siRNA targeting nrf2, an siRNA targeting srbp, an shRNA targeting a pentose phosphate pathway enzyme, an shRNA targeting gluocse-6-phosphate dehydrogenase, an shRNA targeting nrf2, an shRNA targeting srbp, and butathione sulfoximine or a vector or virus encoding any of the aforementioned peptides, proteins, or RNAs, or an analog or precursor of any of the aforementioned compounds, or a pharmaceutically acceptable salt of any of the foregoing substances.

24. The method of claim 21 further comprising administering a reactive oxygen species modulator.

25. The method of claim 21 further comprising administering a proteasome inhibitor.

26. The method of claim 21 further comprising administering an anti-cancer chemotherapeutic agent or a pharmaceutically acceptable salt thereof other than the autophagy inhibitor and other than the at least one of an NADPH modulator or a glutathione modulator.

27. The method of claim 26, wherein the anti-cancer chemotherapeutic agent includes at least one substance selected from the group consisting of oxaliplatin, capecitabine, bevacizumab, docetaxel, paclitaxel, carboplatin, ixabepilone, androstenedione, and testosterone, or a pharmaceutically acceptable salt of any of the foregoing substances.

28. A method of identifying compositions that inhibit or kill quiescent cells comprising:

identifying a target by analyzing at least one of the metabolic flux, gene expression, protein expression, mircoRNA content, histone modification, signaling pathway activity, or physiology of quiescent cells;

identifying a candidate inhibitor of the target; and

exposing a quiescent cell to the candidate inhibitor and identifying whether the candidate inhibitor inhibits or kills the quiescent cell.

29. The method of claim 28, wherein the step of exposing includes administering the candidate inhibitor to a model organism.

30. The method of claim 28, wherein the step of exposing includes administering the candidate inhibitor to a human.

31. A method of identifying compositions that inhibit or kill quiescent cells comprising exposing a quiescent cell to at least one candidate inhibitor and monitoring the physiology of the quiescent cell.

32. The method of claim 31, wherein the step of exposing includes administering the at least one candidate inhibitor to a model organism.

33. The method of claim 31, wherein the step of exposing includes administering the at least one candidate inhibitor to a human.

34. A method of inducing apoptosis comprising exposing at least one of a cell, a cell culture, a tissue, an organ, an organism or a human to a composition comprising an autophagy inhibitor and at least one of an NADPH modulator or a glutathione modulator.

35. The method of claim 34, wherein the composition further comprises a reactive oxygen species modulator.

36. The method of claim 34, wherein the composition further comprises a proteasome inhibitor.

37. A method of sensitizing quiescent cells to proteasome inhibitors comprising exposing a cell, a cell culture, a tissue, an organ, an organism or a human to an autophagy inhibitor and at least one of an NADPH modulator or a glutathione modulator.

38. A composition comprising DHEA and an autophagy inhibitor.

39. A method of inhibiting or killing a quiescent cell comprising exposing the quiescent cell to DHEA and an autophagy inhibitor.

40. A method of treating cancer comprising administering DHEA and an autophagy inhibitor to a cancer patient.